ClinicalTrials.gg
Status unknownNCT05077111VATSUpdated Oct 14, 2021

A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia

A Phase 4 interventional study of Thoracic Epidural Anesthesia and General Anesthesia with One Lung Ventilation in Pleural Effusion, Malignant, Pleural Mesothelioma and Pleural Empyema, sponsored by Mohamed Reda Ashour. Status unknown at 1 site in Egypt. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-14.

Sponsored by Mohamed Reda Ashour · Phase 4, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Jan 2020, registered Sep 2021).
Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

Video-assisted thoracic surgery (VATS) is usually performed with general anesthesia and single lung ventilation. However, performing thoracic surgery under awake regional anesthesia has several potential advantages including avoidance of airway trauma and ventilator dependence associated with endotracheal intubation, besides promoting enhanced recovery after surgery and shorter mean hospital stay.

Read the detailed description

The aim of this study is to investigate the feasibility and the effect of Thoracic Epidural Anaesthesia for awake thoracic surgery to speed up recovery in patients as well as avoiding the complications accompanying General Anesthesia with one lung ventilation.

Type of Study: Prospective randomized clinical study. Study Setting: This study will be conducted in Ain Shams University Hospitals..

Study Period: Expected for two years starting from 2019.

Sampling Method: Randomized sampling by a computer generated random numbers table.

Sample Size: 40 patients. Sample size was calculated using PASS 11 program for sample size calculation and according to the (Pompeo et al., 2004) study, the mean PaO2 perioperatively in the awake group = -3±1.5 mmHg and in the second group = -6.5±1.83 mmHg. Sample size of 40 cases per group (total 40) can detect this difference with power 100% and α-error 0.05.

02

Conditions studied

  • Pleural Effusion, Malignant
  • Pleural Mesothelioma
  • Pleural Empyema
  • Pulmonary Diseases or Conditions
  • Pleural Neoplasms
  • Pulmonary Atelectasis
  • Pleural Diseases
  • Pericardial Effusion
  • Mediastinal Lymphadenopathy
  • Pneumothorax and Air Leak
  • Hemothorax
  • Pyopneumothorax

Keywords

  • thoracocentesis,
  • pleural, biopsy, wash, effusion,
  • ventilation
  • thoracic epidural
  • non intubated VATS,
  • pericardiocenthesis
03

In context

Pleural Effusion, Malignant

169 studies on the registry are indexed under Pleural Effusion, Malignant; 39 are open to participants now.

This study's planned enrollment of 40 is below the median of 55 across 125 interventional studies indexed under Pleural Effusion, Malignant.

Browse Pleural Effusion, Malignant studies →

Lead sponsor

This is the only study on the registry with Mohamed Reda Ashour as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ASA less than or equal II.
  • The procedure expected to be completed within 2 hours.

Exclusion criteria

Exclusion Criteria:

  • Patients with expected difficult airway management.

    • Hemodynamically unstable patients.
    • Persistent cough or high airway secretions.
    • Severe Emphysema or clinical signs of active infectious disease.
    • Hypoxemia (PaO2 \<60 mmHg) or hypercarbia (PCO2 >50 mmHg)
    • Coagulopathy ( >1.5).
    • Obesity ( >30 Kg/m 2 ).
    • Infection at the injection site, allergy to local anesthetics.
    • Neurological disorders: seizures, intracranial mass or brain edema.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Group A

    sole Thoracic Epidural Anesthesia

    Procedure: Thoracic Epidural Anesthesia

  • Active comparator
    Group B

    General Anesthesia with One Lung Ventilation

    Procedure: General Anesthesia with One Lung Ventilation

Interventions

  • ProcedureThoracic Epidural Anesthesia

    Group A pre-medicated once using Midazolam 3-4mg intravenous (IV) and Fentanyl 50mcg, placed in the setting position. Using a winged 18G (Gadge), 9cm length Tuohy Epidural needle, a 20G springwound closed tip epidural catheter be inserted between T3-T4. A test dose (5ml) 2% Lidocaine given, followed by 5-8 ml Bupivacaine 0.5% and 50mcg Fentanyl as a loading dose. Further top-up dose of 5 ml Bupivicaine 0.5% after 45 minutes.

  • ProcedureGeneral Anesthesia with One Lung Ventilation

    Group B premedicated once by 3-4mg Midazolam IV, Ranitidine 50mg, Metoclopramide 10mg and Dexamethasone 4mg. Preoxygenation with 100% O2. Induction of anesthesia with Propofol (2mg/kg) and Fentanyl (1mcg/kg). Tracheal intubation by 37-39 Fr Double Lumen Endotracheal Tube insertion facilitated with Cisatracurium 0.1mg/kg. and confirmation of its position by Fiberoptic Bronchoscopy. Selective Lung Ventilation strategy can be performed through the endobroncheal tube of the non operated lung once needed. Anesthesia maintained with Isoflurane (1-2%) and Cisatracurium (0.05mg/kg per dose). Later, anesthesia discontinued and extubation after full neuromuscular recovery after reversal of muscle relaxant by Neostigmine (0.05mg/kg) and Atropine (0.02mg/kg).

06

What researchers measure

Primary outcomes

  1. Perioperative changes in blood gases

    Ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2), arterial carbon dioxide tension (PaCO2). Hypoxemia is defined as peripheral oxygen saturation (SpO2) \&lt; 92% on room air with a need for oxygen supplementation.

    Time frame: Imediately before operation, intraoperatively per hour, and postoperatively till 24 hours

Secondary outcomes

  1. Postoperative pain

    The Visual Analogue Scale (VAS) consists of a 10 cm straight line with the endpoints defining extreme limits of "no pain at all" (0 cm) and "pain as bad as it could be" (10 cm). The patient is asked to mark his pain level on the line between the two endpoints. The distance between 0 and the mark then defines the subject pain score.

    Time frame: Postoperatively at 3,12 and 24 hours

  2. Postoperative opioid needs

    Pethidine consumption

    Time frame: Postoperatively during the 24 hours after regaining sensation

  3. Hospital stay

    Time frame: from day of operation to discharge; average, 5 days

  4. Perioperative changes in heart rate

    heart rate (HR) in beats per minute (bpm)

    Time frame: Immediately before the operation, intraoperatively per hour, and postoperatively till 24 hours

  5. The onset of ambulance.

    Rate of occurence of falling after ambulance will be recorded in each group.

    Time frame: During the 24 hours after regaining of full motor power

  6. Number of episodes of Post Operative Nausea and Vomiting (PONV)

    Time frame: During the 24 hours postoperatively

  7. Perioperative changes in mean arterial pressure

    mean arterial pressure (MAP) in mmHg

    Time frame: Immediately before the operation, intraoperatively per hour, and postoperatively till 24 hours

07

Study locations

1 site
  • Ain Shams University
    Cairo, 1156, Egypt
08

References and documents

Publications

  • Chen KC, Cheng YJ, Hung MH, Tseng YD, Chen JS. Nonintubated thoracoscopic lung resection: a 3-year experience with 285 cases in a single institution. J Thorac Dis. 2012 Aug;4(4):347-51. doi: 10.3978/j.issn.2072-1439.2012.08.07. PubMed 22934136 ↗
  • Deng HY, Zhu ZJ, Wang YC, Wang WP, Ni PZ, Chen LQ. Non-intubated video-assisted thoracoscopic surgery under loco-regional anaesthesia for thoracic surgery: a meta-analysis. Interact Cardiovasc Thorac Surg. 2016 Jul;23(1):31-40. doi: 10.1093/icvts/ivw055. Epub 2016 Mar 16. PubMed 26984963 ↗
  • Pompeo E, Mineo D, Rogliani P, Sabato AF, Mineo TC. Feasibility and results of awake thoracoscopic resection of solitary pulmonary nodules. Ann Thorac Surg. 2004 Nov;78(5):1761-8. doi: 10.1016/j.athoracsur.2004.05.083. PubMed 15511470 ↗
  • Pompeo E, Sorge R, Akopov A, Congregado M, Grodzki T; ESTS Non-intubated Thoracic Surgery Working Group. Non-intubated thoracic surgery-A survey from the European Society of Thoracic Surgeons. Ann Transl Med. 2015 Mar;3(3):37. doi: 10.3978/j.issn.2305-5839.2015.01.34. PubMed 25815298 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: starting 6 months after publication

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Sep 2021, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2021
First posted
Oct 14, 2021
StartActual
Jan 15, 2020
Primary completionActual
Sep 15, 2021
CompletionEst.
Oct 15, 2021
Last update
Oct 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05077111
Lead sponsor
Mohamed Reda Ashour
Responsible party
Mohamed Reda Ashour (Assistant lecturer, Dept of Anesthesia, Intensive Care and Pain Management, Ain Shams University) — Sponsor-investigator
First posted
Oct 14, 2021
Start date
Jan 15, 2020
Primary completion
Sep 15, 2021
Completion
Oct 15, 2021 (estimated)
Last update
Oct 14, 2021

Study contacts

Samia A M Abdel Latif, Professor
study chair · Department of Anesthesia, Intensive care and pain management, Ain Shams University.
Waleed El Taher, Professor
study director · Department of Anesthesia, Intensive care and pain management, Ain Shams University.
Hany H El Sayed, Professor
study director · Department of Thoracic Surgery, Ain Shams University.
Ahmed F Koraitim, MD
study director · Department of Anesthesia, Intensive care and pain management, Ain Shams University.
Mohamed A A alhadidy, MD
study director · Department of Anesthesia, Intensive care and pain management, Ain Shams University.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion